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Secretion of acid sphingomyelinase is affected by its polymorphic signal
peptide
Abstract

Background: Acid sphingomyelinase (ASM) catalyses the hydrolysis of sphingomyelin into ceramide, which
acts as a lipid messenger that regulates important cellular functions. Deregulated ASM activity has been
reported for different common diseases, but the mechanisms regulating ASM activity are still debated. ASM
contains an exceptional signal peptide which is polymorphic due to a variable number of a hexanucleotide
sequence that determines the length of the hydrophobic core. We investigated the impact of the signal peptide
polymorphism on the regulation of ASM activity and secretion in vivo and in vitro. Methods and Results:
Subjects homozygous for the rare 4-repeat allele displayed significantly lower secreted ASM activity than
subjects homozygous for the common 6-repeat allele. In vitro, overexpression of ASM variants encoded by 2,
8 or 9 repeats resulted in a significantly lowered ASM secretion rate. Treatment of ASM-overexpressing cells
with tumour necrosis factor α induced secretion of ASM, and the secretion rate was highest for the most
common ASM variant encoding 6 repeats compared to other naturally occurring variants. Conclusion: We
provide evidence that the polymorphic ASM signal peptide regulates ASM secretion. It might be an
evolutionary mechanism to increase ASM secretion potential, whereas an increase in lysosomal ASM activity
is limited due to deleterious cellular effects.
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Abstract
Background: Acid sphingomyelinase (ASM) catalyses the hydrolysis of sphingomyelin
into ceramide, which acts as a lipid messenger that regulates important cellular functions.
Deregulated ASM activity has been reported for different common diseases, but the
mechanisms regulating ASM activity are still debated. ASM contains an exceptional signal
peptide which is polymorphic due to a variable number of a hexanucleotide sequence that
determines the length of the hydrophobic core. We investigated the impact of the signal
peptide polymorphism on the regulation of ASM activity and secretion in vivo and in vitro.
Methods and Results: Subjects homozygous for the rare 4-repeat allele displayed significantly
lower secreted ASM activity than subjects homozygous for the common 6-repeat allele. In
vitro, overexpression of ASM variants encoded by 2, 8 or 9 repeats resulted in a significantly
lowered ASM secretion rate. Treatment of ASM-overexpressing cells with tumour necrosis
factor α induced secretion of ASM, and the secretion rate was highest for the most common
ASM variant encoding 6 repeats compared to other naturally occurring variants. Conclusion:
We provide evidence that the polymorphic ASM signal peptide regulates ASM secretion. It
might be an evolutionary mechanism to increase ASM secretion potential, whereas an increase
in lysosomal ASM activity is limited due to deleterious cellular effects.
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Acid Sphingomyelinase (ASM, EC 3.1.4.12) generates ceramide by hydrolysing
sphingomyelin, and it is therefore a key regulator of cellular sphingolipid metabolism [1].
The generation of ceramide is an important cellular reaction to stressful events [2, 3].
Ceramide molecules aggregate spontaneously and fuse to large macrodomains [4-6]. These
macrodomains play an important role in signal transduction processes and impact signal
cascades [7, 8]. Ceramide and its metabolites act as lipid messengers. They promote a
variety of cellular processes, ranging from apoptosis, senescence, differentiation, migration,
angiogenesis, and autophagy to inflammation [9-11]. The balance between apoptosis and
proliferation in the cell is maintained by the complex interplay between two bioactive
sphingolipids. Increased ceramide levels promote apoptosis, whereas an increase in the
phosphorylated metabolite of ceramide, sphingosine-1-phosphate, counteracts this effect
by inducing proliferation [12]. This ‘ceramide / sphingosine-1-phosphate rheostat’ concept
describes how the balance between cell death and cell growth is regulated [12, 13]. Among
the enzymes regulating the dynamic balance between the bioactive lipids, ASM holds a
prominent position in that it generates the first bioactive molecule in this rheostat.
The sphingomyelin phosphodiesterase 1 (SMPD1) gene coding for ASM gives rise to
two distinct enzymes. Upon processing a common precursor protein inside the Golgi,
the secreted form (S-ASM) is finally released into the extracellular space, whereas the
lysosomal form (L-ASM) is targeted to the endo-lysosomal compartment [14, 15]. As a
result of the differential post-translational processing, L- and S-ASM are characterised by
distinct biochemical properties. L-ASM encounters zinc during its processing steps inside
the lysosome, whereas the activity of S-ASM requires additional zinc [16]. Both forms are
glycosylated during Golgi trafficking, but only S-ASM is converted into a complex glycosylated
protein [17, 18]. Furthermore, both forms differ regarding their first amino acid at the
N-terminus [16, 19-22].
Cytokines and other stimulating agents have differential effects on L- and S-ASM. In vivo,
the induction of a systemic inflammation in mice by the application of lipopolysaccharide,
tumour necrosis factor α (TNFα), or interleukin (IL) 1β is accompanied by increased S-ASM
levels [23]. Data about the effects on L-ASM in this context has not been reported. The coregulation of S- and L-ASM activity was addressed in several cell culture systems. Romiti et al.
[24] observed an increased S-ASM release from thrombin-stimulated platelets accompanied
by decreased cellular L-ASM activity. Similarly, Jenkins et al. [15] observed increased S-ASM
activity in MCF7 cells treated with phorbol myristate acetate accompanied by decreased
L-ASM activity. The treatment with IL1β or TNFα in the same study resulted in increased
S-ASM activity without affecting L-ASM activity [15]. Following treatment with IL1β,
interferon (IFN) β, or IFNγ, Marathe et al. [25] observed that S-ASM activity increased by 2 to
3.5-fold in human umbilical vein endothelial cells (HUVECs), and L-ASM activity decreased
slightly. Thus, stimulation might selectively increase short-term S-ASM activity and secretion
at the expense of L-ASM activity.
There is also emerging evidence that L- and S-ASM might differ in their contribution
to specific pathologic states. Dramatically decreased L-ASM activity causes Niemann-Pick
disease (NPD) types A and B, due to a variety of inherited missense mutations in the SMPD1
gene [26]. Low ceramide levels can be found in different types of cancer like colon cancer [27]
and glioma [28]. Elevated L-ASM activity in human primary material has been described for
Alzheimer’s dementia [29], major depression [30], alcohol dependence [31] and infections
[32]. Using murine models it was shown that L-ASM activity is increased in status epilepticus
[33] and cystic fibrosis [34]. S-ASM activity is increased in patients suffering from alcohol
dependence [35], Morbus Wilson [36], chronic heart failure [37], sepsis [38] and chronic
hepatitis C [39]. S-ASM was also increased in murine models of arteriosclerosis [40],
pulmonary edema [41] and emphysema [42].
Despite the huge number of clinically important missense mutations in the SMPD1
gene, only a few reports have addressed the prevalence of common variants of ASM and their
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possible contributions to human disease. In a re-sequencing analysis of the coding region
of SMPD1 [43] we estimated that there are three common non-synonymous polymorphic
sites with a frequency of >5% in the German population. An additional single nucleotide
polymorphism (SNP) encoding the variant p.A487V, which was originally assumed to be
a clinically relevant missense mutation, occurred with a frequency of about 1% [43]. The
only common non-synonymous SNP that affects the mature ASM enzyme is rs1050239
(c.1522G>A; p.G508R) with a minor allele frequency between 16% and 27% in different
studies [44-46]. The polymorphism results in the amino acid substitution Gly>Arg at position
508 in the C-terminus of ASM and it is associated with altered cholesterol levels, familial
history of coronary artery disease [44], self-reported allergy and decreased in vivo S-ASM
activity [45]. The two other common polymorphisms, rs1050228 (c.107T>C; p.V36A) and a
hexanucleotide repeat (c.108GCTGGC(3_8); p.37LA(3_8)) reside within the putative signal
peptide of the ASM pro-form that is not part of the mature enzyme. The signal peptide was
shown to be essential for the production of an intact enzymatically active mature ASM, and
ASM constructs with N-terminal truncations of the signal sequence lacked catalytic activity
[17]. Wan and Schuchman [47] were the first to analyse the polymorphic hexanucleotide
repeat encoding a variable number of Leu-Ala (LA) repeats. They identified five alleles
with different repeat numbers, but the frequencies were similar for healthy individuals
and patients with NPD types A and B. Recently, Dastani et al. [44] observed that the repeat
number was associated with the prevalence of hypertension and plasma triglyceride levels
in people with low high-density lipoprotein cholesterol.
In the present study, we combined clinical and biochemical analyses to investigate the
hypothesis that the polymorphic site in the signal peptide of ASM can affect ASM activity.
We found evidence from both approaches that predominantly S-ASM activity is regulated
differentially by the polymorphic site. In vivo, S-ASM activity was decreased in subjects
homozygous for 4 repeats compared to those with the most prevalent motif of 6 repeats. In
vitro studies elucidated that extreme length of the signal peptide decreases the secretion of
ASM without affecting cellular ASM activity. Interestingly, the signal peptide polymorphism
affects the secretion of ASM induced by the inflammatory cytokine TNFα. The secretion rate
was significantly lower for the 4LA-repeat ASM variant compared to the ASM wild-type with
6LA-repeat. Thus, despite the signal peptide being cleaved very early in ASM maturation, it
has significant influence on the post-cleavage functioning of ASM. The signal peptide might
serve as an evolutionary evolved mechanism to boost ASM secretion potential, although the
increase in L-ASM activity is limited due to deleterious cellular effects.
Clinical study
Study sample. ASM genotypes and ASM activity were initially analysed in 156 healthy individuals
enrolled in the GENES study [45, 48-50]. Further data were obtained from the ASPECT control group (n=133)
[31]. All studies were carried out at the Department of Psychiatry and Psychotherapy at the University of
Erlangen-Nuremberg. The study protocols were approved by the local Ethics Committee and conducted in
accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
Genotyping of ASM. Genomic DNA was isolated from whole blood using the Gentra Puregene Blood Kit
(Qiagen, Hilden, Germany). The genotyping of rs1050239 was described previously [45]. The repeat number
variation was determined by capillary electrophoresis of fluorescent-labelled PCR products on an ABI Prism
3100 Genetic Analyzer (Applied Biosystems, Carlsbad, CA). Previously described oligonucleotides [47] ASM_
repeat_fw (5’-GGACTCCTTTGGATGGGCCT-3’) and ASM_repeat_rev*FAM (5’-CTTTGCAGATTGGGCAGG-3’)
were used with the following PCR conditions: 1.5 U Tfi polymerase (Invitrogen, Darmstadt, Germany), 300
µM dNTPs, 1.5 mM MgCl2, 240 nM of each oligonucleotide, and 50 ng of genomic DNA in a total volume of 15
µl, which were incubated initially for 2 min at 94°C, and subjected to 30 cycles of 30 s at 94°C, 1 min at 58°C,
and 1 min at 72°C, and finished for 3 min at 72°C on a Labcycler (Sensoquest, Göttingen, Germany). SNP
rs1050228 was determined by PCR and cycle sequencing using the primers 5’-AGGGCTGGCTAGGGTCCAG-3’
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Overexpression studies of ASM variants
Construction of expression plasmids. Cloning of the ASM wild-type-FLAG-N2 construct [51] into the
pmCherry-N1 expression vector (Clontech, Mountain View, CA, USA) was carried out using the In-Fusion
Advantage PCR Cloning Kit according to the manufacturer’s instructions (Clontech, Mountain View, CA, USA).
The primers for this procedure were: 5’-TCAGATCTCGAGCTCAAGCTTGCCGCCATGCCCCGCTACGGAGC-3’
(forward) and 5’-CTCACCATGGTGGCGACCGGTACGCAAAACAGTGGCCTTGG-3’ (reverse). The cycle
parameters were as follows: initial denaturation at 95°C for 2 min, 35 cycles of 98°C for 20 sec, 68°C for 15
sec, and 68°C for 1 min, and a final extension at 68°C for 5 min. Constructs were sequenced completely to
exclude any mutations.
The QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) was used to mutate
the ASM wild-type sequence by PCR. Mutagenesis was done according to the manufacturer’s instructions
starting from the ASM wild-type-cherry construct with 6 hexanucleotide repeats using the forward primer
5’-TGGTGCTGGCGCTGGCTCTGT-3’ to obtain the ASM-cherry construct with 5 repeats. Successively, all
further ASM-cherry variants containing different numbers of the repeat were derived. The cycle parameters
were as follows: initial denaturation at 95°C for 1 min, 18 cycles of 95°C for 50 sec, 60°C for 50 sec, and 68°C
for 6 min, and a final extension at 68°C for 7 min. Constructs were sequenced completely to exclude any
spontaneous further mutations.
Cell Culture. H4 cells (Promochem, Wesel, Germany) were cultured in DMEM supplemented with 10%
(v/v) FCS and 4 mM L-glutamine. Cells were maintained at 37°C in a humidified atmosphere with 8.5% CO2
as recommended by the supplier and monitored for potential mycoplasma infection using the MycoAlert
Mycoplasma Detection Kit (Lonza, Cologne, Germany). All reagents used for cell culture were purchased
from Biochrom (Berlin, Germany). For transfection purposes, cells were grown to 60% confluence in 6-well
plates with 2 ml of culture medium. Transfections were performed by the calcium phosphate precipitation
procedure. 7.5 µg of plasmid DNA were mixed with 2x N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic
acid (BES) buffer [50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.98; all chemicals were obtained from
Sigma-Aldrich (Munich, Germany)]. This mixture also contained 10 µl of 2.5 M calcium chloride. This was
then incubated for 20 min at room temperature, and added to cells. The culture medium was changed 17 h
after transfection. The transfection efficiency was approximately 70-80%, as determined by the number of
GFP-positive cells after a parallel control transfection with the expression vector pmaxFP-green-C (Lonza,
Cologne, Germany). Cells were serum-starved overnight and stimulated with TNFα (50 ng/ml; Promokine,
Heidelberg, Germany) for 24 h. Transfected cells were lysed in RIPA buffer [50 mM Tris-HCl (pH 7.5), 150
mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (Sigma-Aldrich, Munich, Germany), into which
were dissolved complete protease inhibitor tablets from Roche (Mannheim, Germany)]. Cell debris was
removed by centrifugation at 1,000 g for 5 min at 4°C. Conditioned medium was collected and centrifuged
at 800 g for 5 min at 4°C.
Acetone protein precipitation. To precipitate protein from the conditioned medium, the acetone protein
precipitation method was applied. 1.5 ml of acetone that was pre-cooled to −20°C was added to 500 µl of
conditioned medium. Upon vortexing, an incubation step was performed for 120 minutes at −20°C. After
centrifuging for 10 minutes at 13,000 g, the supernatant was discarded, and the pellet was air-dried. For
Western blotting, the pellet was dissolved in 50 µl of RIPA buffer.
Peptide-N-glycosidase F digestion (PNGase F). To remove N-linked glycosylation, PNGase F (SigmaAldrich, Munich, Germany) digestion was applied according to the manufacturer’s instructions. 10 µl of 250
mM phosphate buffer at pH 7.5 along with 2.5 ml of 2% SDS with 1 M 2-mercaptoethanol were added to 30
µl of RIPA buffered cell lysate. Upon heating at 100 °C for 5 minutes, the mixture was cooled down and 2.5
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and 5’-AGCCCCAGCACTCCTTTCG-3’. PCR was performed in a total volume of 30 µl using 50 ng of genomic
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each oligonucleotide, and 5% v/v dimethyl sulfoxide (DMSO). The cycling conditions (35 cycles) were as
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58°C, and 60 s at 72°C, and analysed on an Applied Biosystems 3730 DNA Analyzer.
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ml of 10% (v/v) Triton X-100 was added. Incubation Table 1. Characteristics of study sample and alwith PNGase F solution (0.01 U) was applied for 3 lele frequencies of SMPD1 polymorphic sites in the
hours at 37 °C. The cleavage pattern was assessed by GENES collective. HWE, Hardy-Weinberg equilibrium; SNP, single nucleotide polymorphism
subsequent Western Blot analysis.
Western blot analysis. The protein concentration of the cell extracts was determined using the
Coomassie (Bradford) Protein Assay Kit (Pierce,
Rockford, USA). Western blot analysis was conducted as described previously [43, 51]. The blots were
incubated for 4 h at 4°C with the primary goat antiSMPD1 antibody (1:200; R&D, Abingdon, UK) and
then for 1 h with secondary rabbit anti-goat IgG antibody, coupled to horseradish peroxidase (1:10,000;
Dianova, Hamburg, Germany). All antibodies were
diluted in 3% milk powder solution (Roth, Karlsruhe,
Germany) and 0.1% Tween 20 in PBS (SigmaAldrich, Munich, Germany). Detection was performed using the chemiluminescence (ECL select)
Western blotting detection system (Amersham,
Munich, Germany) and visualised on a high-sensitivity camera device (FluorSMax, Bio-Rad, Munich,
Germany).
In vitro determination of L- and S-ASM activity. Activity of overexpressed ASM was determined using
the fluorescent substrate BODIPY-C12-sphingomyelin (Invitrogen, Darmstadt, Germany). For L-ASM, 2 µl
of the cell lysate supernatant (typically corresponding to 0.5–2 µg of protein) were added to 116 pmol of
fluorescent substrate in sodium acetate buffer [200 mM sodium acetate pH 5.0, 500 mM NaCl and 0.2% NP40] in a total volume of 100 µl. After incubation for 0.5 to 3 h at 37°C, the fluorescent product ceramide and
uncleaved substrate were extracted by the addition of 250 µl chloroform/methanol (2:1, v/v). Following
vortexing and centrifugation, the lipid phase was concentrated in a SpeedVac vacuum concentrator and
spotted on silica gel 60 plates (Macherey-Nagel, Düren, Germany). Ceramide and sphingomyelin were
separated by thin layer chromatography using chloroform/methanol (4:1, v/v) as a solvent and quantified
on a Typhoon Trio scanner (GE Healthcare, 488 nm excitation and 520 nm emission wavelengths, 280 V, 100
µm resolution) with QuantityOne software (Bio-Rad, Munich, Germany). S-ASM was measured by the same
procedure with additional 500 µM ZnCl2 in the reaction buffer using a sample volume of 1.5 µl serum-free
medium and incubation times of 1–4 h. Measurements were performed at least in triplicates. The enzymatic
activity of L-ASM was calculated as the rate of hydrolysis of sphingomyelin to ceramide per hour and per µg
of protein (pmol/µg/h). The enzymatic activity of S-ASM in the medium refers to the amount of protein of
the respective cell lysate sample (pmol/µg/h).
Data analysis
Deviation from Hardy-Weinberg equilibrium was assessed using chi-square test, and haplotypes
were reconstructed from genotype data using the program PHASE v.2.1.1 [52]. Statistical analyses were
performed with the software package IBM SPSS Statistics version 19. Variables were tested for normal
distribution using the Kolmogorov-Smirnov test. The genetic effect on S- or L-ASM activity was calculated
using ANOVA and Bonferroni post-hoc analysis. For cell culture experiments, statistical significance was
calculated using t-test. A two-sided p-value <0.05 was considered to indicate statistical significance. All
results are given as mean value ± standard deviation (SD).

Analysis of the three common coding polymorphisms in the SMPD1 gene
We identified three non-synonymous polymorphic sites with a frequency of >5% (Fig.
1A, Table 1). One of the polymorphisms, the SNP rs1050239 (c.1522G>A referenced to
NM_000543.4; p.G508R referenced to NP_000534.3), is located in the C-terminus of ASM and
associated with decreased S-ASM plasma abundance in vivo [45]. We therefore investigated
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The signal peptide polymorphism impacts S-ASM activity in healthy volunteers
Next, we calculated the effect of all three polymorphisms on the ASM activity in blood
plasma (S-ASM) and in lysates of peripheral blood mononuclear cells (PBMC) (L-ASM) in
156 healthy subjects of the GENES study by one-way ANOVA. Because of the strong effect
of rs1050239 [45] and its association with the other two polymorphisms, we observed
a significant association with S-ASM activity for all three polymorphisms when tested
individually (all p<0.001). However, the influence of the c.107T>C polymorphism was
lost when all three polymorphisms were taken into account simultaneously. None of
the polymorphisms were associated with L-ASM activity (data not shown). For a clearer
analysis, we selected subjects with homozygous repeat configurations (4/4, n=5; 5/5, n=28;
6/6, n=42). This analysis confirmed the significant association of S-ASM activity with the
number of hexanucleotide repeat (F=13.9, df=2, p=7.8x10-6; Fig. 2A). Bonferroni post-hoc
analysis revealed statistically significant differences between subjects with 4 and 6 repeats
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whether the two other common Table 2. Frequency of estimated SMPD1 haplotypes in the
polymorphisms affect ASM activity GENES study
in vivo as well. Notably, rs1050239
is the only common variant that
results in an amino acid substitution
within the mature ASM enzyme.
The two other sequence variants,
SNP rs1050228 (c.107T>C; p.V36A)
and the repeat number variation
of a hexanucleotide sequence, lead
to the modification of the signal
peptide of the pro-pro-form of ASM [18] (Fig. 1B). In previous reports, the polymorphic
site was defined as the degenerated sequence 5’-CTGG(TC)(GT)-3’ [44, 47]. However, by
considering the hexanucleotide motif as 5’-GCTGGC-3’, the genomic situation is reflected
more precisely (for instance, see the description of rs3838786 and rs71056748 in dbSNP),
and it allows for the resolution of a compound polymorphic site into two independent
variations that can be described systematically (Fig. 1C). In addition, their relevance can be
addressed separately from each other.
We analysed the genetic configuration of SMPD1 in detail in the GENES collective of 156
healthy young individuals (Table 1). The polymorphic hexanucleotide sequence occurred
in our sample with 4, 5, 6, and 8 repeats. Alleles displaying 6 repeats were found with the
highest prevalence (50.0%; corresponding to the 7-repeat allele in earlier studies that used
the degenerated hexanucleotide sequence for description). Alleles with 5 repeats occurred
with 41.3% (termed the 6-repeat allele in earlier studies). Alleles with four and eight repeats
occurred with a much lower frequency (6.4 and 2.2%, respectively). These 4 alleles are
combined into nine different genotypes (Fig. 1D). The majority of genotypes (86.5%, n=135)
consisted of 5 and 6 repeats in homozygous or heterozygous configuration (5/5: 17.9%;
5/6: 41.7%; 6/6: 26.9%). 9.6% of the genotypes (n=15) were heterozygous combinations
of one frequent allele (either 5 or 6) and one rare allele (either 4 or 8). Of the remaining
genotypes, five subjects were homozygous for 4 repeats, and one carried the combination
4/8. Thus, more than 50% of the subjects exhibited a heterozygous repeat configuration.
Based on the genetic data for all three polymorphisms, nine haplotypes were reconstructed
using the PHASE program [52]. The predominant haplotype consisted of the combination
c.107C – 6 repeats – c.1522G (C-6-G), accounting for nearly 50% of the alleles (Table 2).
Another 40% of alleles carried the haplotype T-5-A or T-5-G. Thus, the c.107T allele was found
nearly exclusively in combination with 5 repeats and was associated with 4 or 6 repeats in
only 2.3%. Consequently, these haplotypes were termed the ‘naturally predominant’ ASM
variants. As reported before by Dastani et al. [44], SNP c.1522A was preferentially present in
combination with 5 hexanucleotide repeats. Thus, the genotypic distribution in our sample
was similar to that described before.
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(p=0.013) and between those with 5 and 6 repeats (p=1.7x10-5). The results revealed that
S-ASM activity associated with the 6/6 genotype was increased by 52% in comparison to the
5/5 genotype and by 66% compared to the 4/4 genotype. Importantly, 4 and 6 repeats were
both preferentially found in the haplotype with c.107C and c.1522G, making it reasonable
to speculate that the difference in S-ASM activity results indeed from the different length
of the signal peptide. In order to confirm this hypothesis statistically with a greater
number of samples, we combined data from two different studies (GENES and ASPECT, see
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Fig. 1. Common coding polyA.
p.37LA(4_8)
p.G508R
morphisms in the SMPD1
p.V36A
gene. A. Schematic representation of common polymorphic
mature ASM protein
sites within the ASM protein.
The sequence variant p.G508R
B.
C631
H62
(rs1050239; c.1522G>A) is
located in the C-terminus
of the mature enzyme,
while p.V36A (rs1050228;
c.107T>C) and the repeat
number variation p.37LA(3_8)
reside within a predicted MPRYGASLRQSCPRSGREQGQDGTAGAPGLLWMGLVLALALALALALALSDSRVLWAPAEA HPL
transmembrane region of the
transmembrane helix
putative signal peptide. The
C.
c.107
putative signal peptide (aa
5‘-GGC
CTG
G(C/T)G
CTG GCG CTG GCG CTG GCG CTG GCG CTG GCG CTG GCT CTG TCT-3‘
1–48) is indicated by a dark
2
4
5
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3
6
grey filling. B. The predicted
Gly Leu Ala/Val Leu Ala Leu Ala Leu Ala Leu Ala Leu Ala Leu Ala Leu Ser
transmembrane domain of
the ASM signal peptide. The
5‘-GGC CTG G(C/T)G CTG GCG CTG GCG CTG GCG CTG GCG CTG GCG CTG GCT CTG TCT-3‘
length of the repeat variation
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6
p.37LA(3_8) determines the
D.
45
hydrophobic core of the pre40
dicted transmembrane helix.
35
The amino acid H62 is the pu30
tative signal peptide cleavage
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site. C. Resolution of the com20
pound polymorphic site in the
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ASM signal peptide into two
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distinct polymorphisms. The
5
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phism c.107T>C is followed
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4/4
4/5
4/6
5/5
5/6
6/6
4/8
5/8
6/8
by a variable repeat number
Genotype
(Hexanucleotide-repeats)
of the hexanucleotide motif
5’-GCTGGC-3’ (upper lane). The number of repeats translates into the respective number of Leu-Ala dipeptides which comprise the core of a putative transmembrane domain. The SNP c.107T>C determines
whether the hypophobic core is extended at the N-terminal end by another Leu-Ala instead of a Leu-Val
dipeptide. At the C-terminal site the hydrophobic core is terminated by a non-polymorphic Leu-Ser dipeptide (middle lane). Using the degenerated sequence 5’-CTGG(TC)(GT)-3’ for the description of the genomic
situation obscures the compound nature of the polymorphic site (lower lane). The nucleotide sequence of
the reference NM_000543.4 (Pos. 100–150) and the amino acid sequence of the reference NP_000534.3
(Pos. 34–50) are given. D. Genotype prevalence. The genotype frequencies of the repeat motif varied highly
in our study sample (n=156). The combinations of 5/6 (42%), 6/6 (27%), and 5/5 (18%) repeats are the
genotypes with the highest prevalence.
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Fig. 2. The signal peptide polymorphism impacts SASM activity in healthy volunteers. A. The 4-repeat
genotype is associated with lower S-ASM activity.
One-way ANOVA revealed statistically significant
differences in S-ASM activity between healthy volunteers homozygous for 4 (n=5), 5 (n=28), and 6
(n=42) repeats (F=13.9, df=2, p=7.8x10-6). Bonferroni post-hoc analysis revealed significant differences between 4 and 6 (p=0.013) and 5 and 6
(p=1.7x10-5) repeats. The boxplots show the median
with the 25/75 percentiles. B. Graphical representation of the independent effects of the repeat length
and c.1522G>A on S-ASM activity. Genetic data and
z-transformed values for S-ASM activity from different studies (GENES and ASPECT, n=289) were
combined. ANOVA confirmed that the hexanucleotide repeat had a significant effect on S-ASM activity independent from the influence of rs1050239 /
c.1522G>A. Numbers of homozygous samples in this
analysis: 4, n=6; 5, n=42; 6, n=74. Data for S-ASM
activity represent z-transformed values; error bars
denote SD.
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The signal peptide polymorphism impacts S-ASM but not L-ASM activity in vitro
To further investigate the significance of the effect of the polymorphic hexanucleotide
repeat for ASM biology, we performed in vitro studies using a cultured cell line. Plasmids
coding for ASM variants with 1 to 9LA repeats combined with the LV dipeptide (p.V36) in the
signal peptide and glycine (p.G508) at position 508 in the C-terminus of ASM were generated
by site-directed mutagenesis and transiently overexpressed in H4 cells. The conditioned
medium was collected and analysed for enzymatic activity of S-ASM. Overexpression of
the ASM variant containing 6LA repeats, which is defined as the ASM wild-type (GenBank
Accession Number NM_000543.4), significantly increased ASM activity levels by 120-fold
compared to endogenous levels with a control plasmid. Similar results were obtained for ASM
variants with 3, 4, 5, or 7LA repeats. In contrast, ASM variants containing the extreme motifs
of 1, 2, 8, or 9LA repeats resulted in significantly lower levels of S-ASM activity compared to
the ASM wild-type with 6LA-repeat (Fig. 3A).
To determine ASM protein expression levels, total proteins were precipitated from
conditioned medium and subjected to Western blot analyses. Analogous to S-ASM activities,
the expression of the protein corresponding to the size of the active ASM isoform was very
strong upon overexpression of ASM variants with 3, 4, 5, 6, and 7LA repeats, but hardly
detectable for ASM variants with the extreme motifs of 1, 2, 8, or 9LA repeats (Fig. 3B).
The overexpression of ASM wild-type with 6LA-repeat in H4 cells significantly increased
the L-ASM activity in cell lysates by about 9-fold compared to endogenous levels. Except for
the ASM variant with the 1LA-motif, no significant differences in ASM activity were found
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material and methods) and performed three-way ANOVA considering the effect of all three
polymorphisms in a single analysis. This analysis confirmed that the hexanucleotide repeat,
but not c.107T>C, had a significant effect on S-ASM activity independent from the influence
of rs1050239 / c.1522G>A (hexanucleotide repeat: F=14.8, df=3, p=4.01x10-4; rs1050228:
F=0.430, df=2, p=0.651; rs1050239: F=15.1, df=2, p=9.23x10-5). A graphical representation
of the independent repeat motif effect is given in Fig. 2B.
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between the ASM variants (Fig. 3C). Western blot analyses showed that the variant ASMcherry constructs were translated into proteins of the predicted sizes. Using the antibody
against ASM allows for the detection of an ASM-cherry pre-pro-form (ASM including
the varying signal peptide (75 kDa) and the cherry-tag (30 kDa) adding up to a total of
approximately 100 kDa), an ASM-cherry pro-form (ASM including cherry-tag but cleaved
signal peptide), a C-terminally processed ASM form (ASM without cherry-tag; 75 kDa), and
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5 or 7LA repeats. In contrast, the ac50
tive 85 kDa form was hardly detectable for ASM variants with the extreme motifs of 1, 2, 8 or 9LA repeats. Protein was precipitated from conditioned
medium and analysed by Western blotting. ASM-cherry variants were detected using an anti-ASM antibody.
The cloning vector served as a negative control. C. L-ASM activity. Overexpression of ASM wild-type (6LA) in
H4 cells significantly increased the L-ASM activity in the cell lysates compared to control. Except for the ASM
variant with the 1LA-motif, no significant difference in ASM activity was found for the other ASM variants. Cell
lysates were analysed for L-ASM activity using the enzyme activity assay. Otherwise, methods and statistics
were applied as described in 3A. D. Western blot analysis of cell lysates. Western blot analyses showed that
cherry-tagged ASM variants were translated into proteins of the predicted sizes. With the exception of the ASM
variant with the 1LA-motif, all other variants were expressed to a similar extent as ASM wild-type (6LA). Cell
lysates were subjected to Western blotting. ASM-cherry variants were detected using an anti-ASM antibody. The
cloning vector served as a negative control.
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Fig. 4. The 1LA-motif is not sufficient to translocate ASM into the endoplasmic reticulum. Upon PNGase F
digestion, all detected ASM bands (see Fig. 3D) were shifted to protein sizes minus 10 kDa with the exception of the 1LA variant, for which no shift was detected. H4 cells were transfected with indicated variants,
digested with 0.01U PNGase F for 22 h (“+”), and compared to control conditions (“−“) by Western blotting
using an anti-ASM antibody. The cloning vector served as a negative control.

the active ASM form (proteolytically cleaved ASM; 65 kDa). With the exception of the ASM
variant with the 1LA-motif, all other variants were expressed to an extent similar to that of
the ASM wild-type with 6LA-repeat (Fig. 3D).

TNFα-induced secretion of ASM is influenced by its signal peptide
Due to the impact of the ASM signal peptide on secretion, we investigated the ASM
secretion process more closely. ASM secretion is promoted by inflammatory cytokines, as
shown in in vitro and in vivo models [15, 23, 25]. To investigate the impact of the ASM signal
peptide polymorphism on TNFα-induced secretion, H4 cells were transiently transfected
with the naturally predominant ASM variants. Following stimulation of ASM-transfected
cells with TNFα for 24 h, S-ASM activity increased and L-ASM activity decreased for all
tested ASM variants (Fig. 5A). However, transfection of the ASM wild-type with 6LA-repeat
resulted in a stronger TNFα-induced increase in S-ASM activity and a weaker decrease in
L-ASM activity compared to the other natural variants. Regarding the ratio of S-ASM to
L-ASM activity, the ASM wild-type with 6LA-repeat reached higher levels upon stimulation
compared to the natural ASM variants with 4LA and 5LA repeats. The increase in the ratio
of the S- to L-ASM activity of the 4LA-variant was significantly lower than for the ASM wildtype with 6LA-repeat upon stimulation with TNFα (p=0.047), whereas the 5LA-variant
reached intermediate levels (Fig. 5B). Thus, although the signal peptide is cleaved early in
ASM maturation, the length of its hydrophobic core has significant impact on the secretion of
ASM upon stimulation with TNFα.
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The 1LA-motif does not serve as a functional signal peptide
To analyse whether the 1LA-motif serves as a functional signal peptide and is able to
target the protein into the endoplasmic reticulum (ER), the glycosidase-sensitivity of the
ASM signal peptide variants was investigated. Since N-glycosylation takes place selectively
inside the ER lumen, this analysis indicates if a protein translocates into the ER [53]. Upon
overexpression, cleared lysates were subjected to peptide-N-glycosidase F (PNGase F)
digestion and subsequent Western blot analysis. PNGase F digestion leads to deglycosylation
by releasing asparagine-linked (N-linked) oligosaccharides from glycoproteins, which
results in a decrease of the protein mass of 10 kDa. Without PNGase F digestion, the ASM
wild-type expression pattern was identical to those in the Western blot analysis in Fig. 3D.
Upon PNGase F treatment, ASM protein bands were detected that were reduced to 90+, 90,
65 and 55 kDa. The detection of glycosylated protein forms indicates the translocation of
ASM wild-type into the ER. Compared to ASM wild-type, PNGase F treatment of ASM variants
with LA-repeat>1 resulted in the same immunoreactive pattern. In contrast, the digestion of
the 1LA ASM variant with PNGase F did not show protein bands that represent a glycosylated
protein (Fig. 4). Thus, the 1LA-motif is not sufficient to serve as a signal peptide. The minimal
requirement for a signal peptide seems to start from a 2LA-repeat motif.
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Fig. 5. TNFα-induced secretion is influenced by the ASM signal peptide. A. Influence of TNFα on S- and L-ASM activities.
Upon stimulation with TNFα, S-ASM activity levels increased significantly for all
natural ASM variants, while L-ASM activity levels decreased significantly only for
the 4LA and 5LA-variant compared to respective control conditions. H4 cells were
transfected with 7.5 µg of the respective
ASM-cherry construct. Upon overnight
serum-starvation, cells were stimulated with TNFα (50 ng/ml) for 24 h. Cell
lysates were analysed for L-ASM activity,
and conditioned medium was analysed
for S-ASM activity using the enzyme activity assay. The displayed data represent
mean values of triplicates, and error bars
denote SD. Results were replicated three
times. Statistical significance was calculated with regard to the respective control
condition using t-test (*p<0.05). B. Ratio
between S- and L-ASM activity. Upon stimulation with TNFα, the increase in the Sto L-ASM activity ratio of the 4LA-variant
was significantly lower than for the ASM
wild-type (6LA). The ratio of S- and L-ASM
activity is indicated as the percentage of
the respective control condition. The displayed data represent mean values of n=4
independent experiments measured in
triplicates, and error bars denote SD. Statistical significance was calculated with
regard to the ASM wild-type (6LA) using
t-test (*p<0.05).
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In this study, we combined clinical and biochemical approaches to elucidate how genetic
polymorphisms located within the signal peptide of ASM might influence the regulatory
function regarding expression of the protein. The signal peptide of ASM is remarkable in
several respects. Firstly, usual signal peptides consist of fewer than 25 amino acids (aa)
with a short positively charged N-terminal region (called n-region), a 7- to 15-residue-long
central hydrophobic core (h-region), and a polar C-terminal region (c-region) which defines
the cleavage site [54]. In contrast, the signal peptide of ASM consists of >48 aa comprising an
extended n-region (≥26 aa), a predicted transmembrane domain (TMD) acting as an h-region
(18 to 22 aa, depending on the prediction method used), and an ill-defined c-region which
allows variable post-cleavage N-terminal starting points of the maturated enzyme [16, 19,
22]. Thus, the signal peptide of ASM resembles more of an N-terminal anchor segment (type
II signal anchor) [55, 56] that potentially encodes additional functions beyond the simple
import to the endoplasmic reticulum such as specification of the targeting pathway, the
efficiency of translocation, the timing of cleavage or post-cleavage functions [57]. Secondly,
the hydrophobic core of the predicted TMD is variable in length due to a genetically stable
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polymorphic repeat number variation of a hexanucleotide motif encoding the dipeptide LeuAla. Interestingly, the length of a TMD has a strong impact on the localization of the respective
protein [58, 59]. Thus, the unusual structure of the ASM signal peptide might constitute a
regulatory mechanism that controls the localization and thus the secretion of the enzyme.
A similar effect on secretion exerted by a polymorphic signal peptide was described for
apolipoprotein B (ApoB). Interestingly, ApoB displays a signal peptide polymorphism similar
to that of the ASM, since it also comprises a Leu-Ala motif with an additional insertion (LeuLeu) or deletion (Leu-Ala-Leu) [60] that influences protein secretion rates [61]. In clinical
studies, it has also been shown to influence the serum triglyceride levels [62], cholesterol and
LDL-levels [63], cholesterol transport [64], and the onset of atherosclerosis and ischaemic
heart disease [65, 66]. Thirdly, while the presence of a variable region does not necessarily
prove a functional relevance, the non-random distribution of repeat numbers in the ASM
gene implies that the repertoire of existing alleles has been shaped by selection [67]. We
therefore hypothesized that the polymorphic signal peptide might affect ASM biology.
Importantly, there is also genetic evidence pointing to a functional role of the ASM
signal peptide. In a study of 118 subjects of French-Canadian descent, Dastani et al. [44]
analysed the association of common ASM polymorphisms with severely reduced plasma
high-density lipoprotein (HDL) cholesterol levels. Although the authors’ original hypothesis
of an association with low HDL-cholesterol levels could not be confirmed, they observed
significant differences between affected subjects with 5/5, 5/6, and 6/6 configurations
for hypertension and triglyceride levels. Since Dastani et al. compared only the three most
common genotypes (which comprised nearly 90% of cases, similar to our study), this leaves
the possibility that subjects who carry at least one of the rarer alleles and comprise <10% of
the normal population are affected even more strongly.
Considering the great genotypic diversity among carriers of rare alleles and the strong
linkage disequilibrium with other functional polymorphisms such a hypothesis would be hard
to prove. In our clinical study, we investigated genetic data from 156 volunteers of the GENES
study along with their data on S-ASM activity determined from plasma. In a previous study,
we found that S-ASM activity is a more sensitive marker for a genetic influence compared
to L-ASM activity [45], probably because of the higher turn-over rate of L-ASM [15]. Indeed,
we showed that S-ASM activity, but not L-ASM activity, was associated with the number of
the hexanucleotide motifs in the signal peptide. In order to reduce the genetic diversity of
the sample and to designate the specificity of the effect for the polymorphic signal peptide,
we selected subjects with a homozygous repeat configuration and conducted multi-way
ANOVA. As a result, we found that 4 repeats were associated with a statistically significant
lower S-ASM activity compared to 6 repeats. Five repeats were associated with intermediate
S-ASM levels, but this comparison was confounded by the preferential combination of 5
hexanucleotide repeats with the minor allele of rs1050239 (c.1522A). Interestingly, as
revealed by two-way ANOVA, only the haplotype consisting of 6 repeats together with the
major allele of rs1050239 (which comprises nearly 50% of the predominant haplotype)
gave rise to above-average S-ASM activity, while all other genetic combinations resulted in
below-average S-ASM activity (see Fig. 2B).
Our in vitro data using cloned ASM cDNA encoding different numbers of the
hexanucleotide repeat confirmed the importance of this motif for proper ASM processing.
We defined the minimal requirement for the translocation of the nascent ASM peptide with
two hexanucleotide repeats. Transfection of a cloned variant encoding only one repeat only
slightly increased L- and S-ASM activity. A detailed analysis revealed that this variant is not
glycosylated, indicating that it was not properly imported into the endoplasmic reticulum.
In contrast, cDNA variants encoding between 2 and 9 repeats resulted in L-ASM activity
increased by nine-fold compared to controls. However, L-ASM activity associated with varying
repeat lengths was not different, which is in agreement with our observation in the clinical
sample that common variants do not affect L-ASM activity. Interestingly, S-ASM activity
showed different effects compared to L-ASM activity in our assay. While the transfection
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of the most common variants increased S-ASM activity by 120-fold compared to controls,
transfection of variants with extremely low or high repeat numbers increased S-ASM to a
significantly lower extent. Further analyses revealed that the proteolytic maturation of ASM
was hampered in these variants.
Thus, our analyses revealed that the polymorphic ASM signal peptide affects L- and S-ASM
differentially. Therefore, we questioned whether the polymorphic signal peptide would also
affect ASM activity differentially under stimulating conditions. Our cell culture data showed
a significant increase in S-ASM activity accompanied by a decrease in L-ASM activity upon
stimulation with TNFα. The observation of a significant increase of S-ASM activity at the
expense of decreased L-ASM activity is in line with other studies which addressed the coregulation of L- and S- ASM in response to stimulating agents [15, 24, 25]. However, we
could additionally show that the ASM signal peptide polymorphism influences the balance
between S-ASM release and the concomitant decrease in L-ASM activity significantly. The
increase in the S- to L-ASM activity ratio of the 4LA-variant was significantly lower than for
the ASM wild-type with 6LA-repeat upon stimulation with TNFα.
This genetic effect could have important implications for the immunologic reactions of
individuals carrying 4 repeats. Possibly, the difference in S-ASM activity between individuals
homozygous for 4 repeats and those for 6 repeats in our in vivo study might result from
the current individual and prevalent immunologic reaction. From an evolutionary point
of view, the high number of repeats in humans with the higher adaptive potential in ASM
activity regulation could be advantageous and more recent since the ASM encoding gene
of other primate species with known sequence (Ensembl database) contains consistently
less repeats. Alignment to the ASM wild-type sequence with 6LA-repeat in humans reveals
a 5LA-repeat for Orangutan (Pongo abelii) and Macaque (Macaca mulatta), a 4LA-repeat
for Chimpanzee (Pan troglodytes) and only a 3LA-repeat for Gorilla (Gorilla gorilla gorilla),
Gibbon (Nomascus leucogenys), Bushbaby (Otolemur garnettii), Marmoset (Callithrix jacchus)
and Mouse Lemur (Microcebus murinus).
Overall, the length of the ASM signal peptide TMD could be essential for the exact sorting
and trafficking of ASM into highly specialised vesicles. It was shown that ASM co-localises
with dysferlin to specific cellular vesicles during plasma membrane repair [68] and with
syntaxin 4 upon stress responses to translocate to the plasma membrane via the exocytic
pathway [69]. Interestingly, the syntaxin isoforms display distinct TMD lengths of their
signal peptide that determine their localisation either to the Golgi or the plasma membrane
[59]. Thus, the ASM TMD length seems to be optimised for its specific tasks in the cell.
However, there were some limitations of our study that should be considered. Although
our clinical studies GENES and ASPECT comprised 289 healthy individuals in total, only a
few individuals were homozygous for the rare allele with 4 repeats, which were needed for
more powerful analyses. In our in vitro study, biochemical analyses of ASM resulted in very
similar processing patterns for variants with 3 to 7 repeats, in contrast to the differential
effects already seen for 4 repeats in vivo.
Taken together, our data provide first evidence that the length of the ASM signal peptide
is essential for tapping the full secretion potential of the protein. The consequences of
impaired ASM secretion for clinical populations have yet to be defined.
We thank Stefan Hofmann, Franziska Kreß and Sabine Müller for excellent technical
assistance. The authors are also grateful to Cornelia Kraus from the Department of Human
Genetics in Erlangen for her kind support with the Genetic Analyzer. This work was supported
by the Scholarship Programme ‘Equality for Women in Research and Teaching’, University
Erlangen-Nuremberg (to CR).

Downloaded by:
University of Wollongong
130.130.37.85 - 12/10/2014 4:23:52 AM

Acknowledgements

Cellular Physiology
and Biochemistry

Cell Physiol Biochem 2014;34:1385-1401
DOI: 10.1159/000366345
Published online: October 02, 2014

© 2014 S. Karger AG, Basel
www.karger.com/cpb

1398

Rhein et al.: Function of the ASM Signal Peptide

1
2
3
4
5
6
7
8
9

10
11
12
13
14
15
16
17
18
19
20
21
22

Quintern LE, Weitz G, Nehrkorn H, Tager JM, Schram AW, Sandhoff K: Acid sphingomyelinase from human
urine: Purification and characterization. Biochim Biophys Acta 1987;922:323-336.
Herr I, Wilhelm D, Böhler T, Angel P, Debatin KM: Activation of CD95 (APO-1/Fas) signaling by ceramide
mediates cancer therapy-induced apoptosis. Embo J 1997;16:6200-6208.
Quintans J, Kilkus J, McShan CL, Gottschalk AR, Dawson G: Ceramide mediates the apoptotic response of
wehi 231 cells to anti-immunoglobulin, corticosteroids and irradiation. Biochem Biophys Res Commun
1994;202:710-714.
Kolesnick RN, Goni FM, Alonso A: Compartmentalization of ceramide signaling: Physical foundations and
biological effects. J Cell Physiol 2000;184:285-300.
Holopainen JM, Subramanian M, Kinnunen PK: Sphingomyelinase induces lipid microdomain formation in
a fluid phosphatidylcholine/sphingomyelin membrane. Biochemistry 1998;37:17562-17570.
Nurminen TA, Holopainen JM, Zhao H, Kinnunen PK: Observation of topical catalysis by sphingomyelinase
coupled to microspheres. J Am Chem Soc 2002;124:12129-12134.
Grassmé H, Jekle A, Riehle A, Schwarz H, Berger J, Sandhoff K, Kolesnick R, Gulbins E: CD95 signaling via
ceramide-rich membrane rafts. J Biol Chem 2001;276:20589-20596.
Grassmé H, Riethmüller J, Gulbins E: Biological aspects of ceramide-enriched membrane domains. Prog
Lipid Res 2007;46:161-170.
Carpinteiro A, Dumitru C, Schenck M, Gulbins E: Ceramide-induced cell death in malignant cells. Cancer
Lett 2008;264:1-10.
Pettus BJ, Chalfant CE, Hannun YA: Sphingolipids in inflammation: Roles and implications. Curr Mol Med
2004;4:405-418.
Ogretmen B, Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev
Cancer 2004;4:604-616.
Spiegel S, Cuvillier O, Edsall LC, Kohama T, Menzeleev R, Olah Z, Olivera A, Pirianov G, Thomas DM, Tu
Z, Van Brocklyn JR, Wang F: Sphingosine-1-phosphate in cell growth and cell death. Ann N Y Acad Sci
1998;845:11-18.
Spiegel S, Merrill AH Jr: Sphingolipid metabolism and cell growth regulation. FASEB J 1996;10:1388-1397.
Schissel SL, Schuchman EH, Williams KJ, Tabas I: Zn2+-stimulated sphingomyelinase is secreted by many
cell types and is a product of the acid sphingomyelinase gene. J Biol Chem 1996;271:18431-18436.
Jenkins RW, Canals D, Idkowiak-Baldys J, Simbari F, Roddy P, Perry DM, Kitatani K, Luberto C, Hannun YA:
Regulated secretion of acid sphingomyelinase: Implications for selectivity of ceramide formation. J Biol
Chem 2010;285:35706-35718.
Schissel SL, Keesler GA, Schuchman EH, Williams KJ, Tabas I: The cellular trafficking and zinc dependence
of secretory and lysosomal sphingomyelinase, two products of the acid sphingomyelinase gene. J Biol Chem
1998;273:18250-18259.
Ferlinz K, Hurwitz R, Vielhaber G, Suzuki K, Sandhoff K: Occurrence of two molecular forms of human acid
sphingomyelinase. Biochem J 1994;301:855-862.
Hurwitz R, Ferlinz K, Vielhaber G, Moczall H, Sandhoff K: Processing of human acid sphingomyelinase in
normal and I-cell fibroblasts. J Biol Chem 1994;269:5440-5445.
Bartelsen O, Lansmann S, Nettersheim M, Lemm T, Ferlinz K, Sandhoff K: Expression of recombinant
human acid sphingomyelinase in insect sf21 cells: Purification, processing and enzymatic characterization.
J Biotechnol 1998;63:29-40.
Ferlinz K, Hurwitz R, Moczall H, Lansmann S, Schuchman EH, Sandhoff K: Functional characterization of
the n-glycosylation sites of human acid sphingomyelinase by site-directed mutagenesis. Eur J Biochem
1997;243:511-517.
Qiu H, Edmunds T, Baker-Malcolm J, Karey KP, Estes S, Schwarz C, Hughes H, Van Patten SM: Activation
of human acid sphingomyelinase through modification or deletion of C-terminal cysteine. J Biol Chem
2003;278:32744-32752.
Lansmann S, Ferlinz K, Hurwitz R, Bartelsen O, Glombitza G, Sandhoff K: Purification of acid
sphingomyelinase from human placenta: Characterization and N-terminal sequence. FEBS Lett
1996;399:227-231.

Downloaded by:
University of Wollongong
130.130.37.85 - 12/10/2014 4:23:52 AM

References

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Cell Physiol Biochem 2014;34:1385-1401
DOI: 10.1159/000366345
Published online: October 02, 2014

© 2014 S. Karger AG, Basel
www.karger.com/cpb

1399

Rhein et al.: Function of the ASM Signal Peptide

Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A, Gold PW, Hirsch E, Williams KJ, Licinio J, Tabas I:
Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: A possible link between
inflammatory cytokines and atherogenesis. Proc Natl Acad Sci U S A 2000;97:8681-8686.
Romiti E, Vasta V, Meacci E, Farnararo M, Linke T, Ferlinz K, Sandhoff K, Bruni P: Characterization of
sphingomyelinase activity released by thrombin-stimulated platelets. Mol Cell Biochem 2000;205:75-81.
Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ, Tabas I: Human vascular endothelial
cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis
and ceramide-mediated cell signaling. J Biol Chem 1998;273:4081-4088.
Brady RO, Kanfer JN, Mock MB, Fredrickson DS: The metabolism of sphingomyelin. II. Evidence of an
enzymatic deficiency in Niemann-Pick disease. Proc Natl Acad Sci U S A 1966;55:366-369.
Selzner M, Bielawska A, Morse MA, Rüdiger HA, Sindram D, Hannun YA, Clavien PA: Induction of apoptotic
cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer.
Cancer Res 2001;61:1233-1240.
Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli-Boneschi F, Viani P, Tettamanti G: Ceramide
levels are inversely associated with malignant progression of human glial tumors. Glia 2002;39:105-113.
He X, Huang Y, Li B, Gong CX, Schuchman EH: Deregulation of sphingolipid metabolism in Alzheimer's
disease. Neurobiol Aging 20010;31:398-408.
Kornhuber J, Medlin A, Bleich S, Jendrossek V, Henkel AW, Wiltfang J, Gulbins E: High activity of acid
sphingomyelinase in major depression. J Neural Transm 2005;112:1583-1590.
Reichel M, Greiner E, Richter-Schmidinger T, Yedibela O, Tripal P, Jacobi A, Bleich S, Gulbins E, Kornhuber
J: Increased acid sphingomyelinase activity in peripheral blood cells of acutely intoxicated patients with
alcohol dependence. Alcohol Clin Exp Res 2010;34:46-50.
Grassmé H, Jendrossek V, Riehle A, von Kürthy G, Berger J, Schwarz H, Weller M, Kolesnick R, Gulbins
E: Host defense against pseudomonas aeruginosa requires ceramide-rich membrane rafts. Nat Med
2003;9:322-330.
Mikati MA, Zeinieh M, Habib RA, El Hokayem J, Rahmeh A, El Sabban M, Usta J, Dbaibo G: Changes in
sphingomyelinases, ceramide, Bax, Bcl2, and caspase-3 during and after experimental status epilepticus.
Epilepsy Res 2008;81:161-166.
Teichgräber V, Ulrich M, Endlich N, Riethmüller J, Wilker B, De Oliveira-Munding CC, van Heeckeren
AM, Barr ML, von Kürthy G, Schmid KW, Weller M, Tümmler B, Lang F, Grassmé H, Doring G, Gulbins E:
Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat
Med 2008;14:382-391.
Reichel M, Beck J, Mühle C, Rotter A, Bleich S, Gulbins E, Kornhuber J: Activity of secretory
sphingomyelinase is increased in plasma of alcohol-dependent patients. Alcohol Clin Exp Res
2011;35:1852-1859.
Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H,
Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E,
Lang F: Liver cell death and anemia in wilson disease involve acid sphingomyelinase and ceramide. Nat
Med 2007;13:164-170.
Doehner W, Bunck AC, Rauchhaus M, von Haehling S, Brunkhorst FM, Cicoira M, Tschope C, Ponikowski
P, Claus RA, Anker SD: Secretory sphingomyelinase is upregulated in chronic heart failure: A second
messenger system of immune activation relates to body composition, muscular functional capacity, and
peripheral blood flow. Eur Heart J 2007;28:821-828.
Claus RA, Bunck AC, Bockmeyer CL, Brunkhorst FM, Losche W, Kinscherf R, Deigner HP: Role of increased
sphingomyelinase activity in apoptosis and organ failure of patients with severe sepsis. FASEB J
2005;19:1719-1721.
Grammatikos G, Mühle C, Ferreiros N, Schroeter S, Bogdanou D, Schwalm S, Hintereder G, Kornhuber J,
Zeuzem S, Sarrazin C, Pfeilschifter J: Serum acid sphingomyelinase is upregulated in chronic hepatitis C
infection and non alcoholic fatty liver disease. Biochim Biophys Acta 2014;1841:1012-1020.
Marathe S, Kuriakose G, Williams KJ, Tabas I: Sphingomyelinase, an enzyme implicated in atherogenesis,
is present in atherosclerotic lesions and binds to specific components of the subendothelial extracellular
matrix. Arterioscler Thromb Vasc Biol 1999;19:2648-2658.

Downloaded by:
University of Wollongong
130.130.37.85 - 12/10/2014 4:23:52 AM

Cellular Physiology
and Biochemistry

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

Cell Physiol Biochem 2014;34:1385-1401
DOI: 10.1159/000366345
Published online: October 02, 2014

© 2014 S. Karger AG, Basel
www.karger.com/cpb

1400

Rhein et al.: Function of the ASM Signal Peptide

Göggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schütze
S, Gulbins E, Uhlig S: PAF-mediated pulmonary edema: A new role for acid sphingomyelinase and ceramide.
Nat Med 2004;10:155-160.
Petrache I, Natarajan V, Zhen L, Medler TR, Richter AT, Cho C, Hubbard WC, Berdyshev EV, Tuder RM:
Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med
2005;11:491-498.
Rhein C, Naumann J, Mühle C, Zill P, Adli M, Hegerl U, Hiemke C, Mergl R, Möller H-J, Reichel M, Kornhuber J:
The acid sphingomyelinase sequence variant p.A487V is not associated with decreased levels of enzymatic
activity. JIMD Rep 2013;8:1-6.
Dastani Z, Ruel IL, Engert JC, Genest J Jr, Marcil M: Sphingomyelin phosphodiesterase-1 (SMPD1) coding
variants do not contribute to low levels of high-density lipoprotein cholesterol. BMC Med Genet 2007;8:79.
Reichel M, Richter-Schmidinger T, Mühle C, Rhein C, Alexopoulos P, Schwab SG, Gulbins E, Kornhuber J: The
common acid sphingomyelinase polymorphism G508R is associated with self-reported allergy. Cell Physiol
Biochem 2014;34:82-91.
Schuchman EH, Levran O, Suchi M, Desnick RJ: An MspI polymorphism in the human acid sphingomyelinase
gene (SMPD1). Nucleic Acids Res 1991;19:3160.
Wan Q, Schuchman EH: A novel polymorphism in the human acid sphingomyelinase gene due to size
variation of the signal peptide region. Biochim Biophys Acta 1995;1270:207-210.
Alexopoulos P, Richter-Schmidinger T, Horn M, Maus S, Reichel M, Sidiropoulos C, Rhein C, Lewczuk P,
Doerfler A, Kornhuber J: Hippocampal volume differences between healthy young apolipoprotein E ε2 and
ε4 carriers. J Alzheimers Dis 2011;26:207-210.
Richter-Schmidinger T, Alexopoulos P, Horn M, Maus S, Reichel M, Rhein C, Lewczuk P, Sidiropoulos
C, Kneib T, Perneczky R, Doerfler A, Kornhuber J: Influence of brain-derived neurotrophic-factor and
apolipoprotein E genetic variants on hippocampal volume and memory performance in healthy young
adults. J Neural Transm 2011;118:249-257.
Rhein C, Mühle C, Richter-Schmidinger T, Alexopoulos P, Doerfler A, Kornhuber J: Neuroanatomical
correlates of intelligence in healthy young adults: The role of basal ganglia volume. PLOS ONE
2014;9:e93623.
Rhein C, Tripal P, Seebahn A, Konrad A, Kramer M, Nagel C, Kemper J, Bode J, Mühle C, Gulbins E, Reichel M,
Becker CM, Kornhuber J: Functional implications of novel human acid sphingomyelinase splice variants.
PLOS ONE 2012;7:e35467.
Stephens M, Donnelly P: A comparison of Bayesian methods for haplotype reconstruction from population
genotype data. Am J Hum Genet 2003;73:1162-1169.
Kochl R, Alken M, Rutz C, Krause G, Oksche A, Rosenthal W, Schulein R: The signal peptide of the G proteincoupled human endothelin B receptor is necessary for translocation of the N-terminal tail across the
endoplasmic reticulum membrane. J Biol Chem 2002;277:16131-16138.
von Heijne G: Signal sequences. The limits of variation. J Mol Biol 1985;184:99-105.
von Heijne G: Towards a comparative anatomy of N-terminal topogenic protein sequences. J Mol Biol
1986;189:239-242.
Martoglio B, Dobberstein B: Signal sequences: More than just greasy peptides. Trends Cell Biol 1998;8:410415.
Hegde RS, Bernstein HD: The surprising complexity of signal sequences. Trends Biochem Sci 2006;31:563571.
Bulbarelli A, Sprocati T, Barberi M, Pedrazzini E, Borgese N: Trafficking of tail-anchored proteins: Transport
from the endoplasmic reticulum to the plasma membrane and sorting between surface domains in
polarised epithelial cells. J Cell Sci 2002;115:1689-1702.
Watson RT, Pessin JE: Transmembrane domain length determines intracellular membrane compartment
localization of syntaxins 3, 4, and 5. Am J Physiol Cell Physiol 2001;281:C215-223.
Visvikis S, Chan L, Siest G, Drouin P, Boerwinkle E: An insertion deletion polymorphism in the signal
peptide of the human apolipoprotein B gene. Hum Genet 1990;84:373-375.
Sturley SL, Talmud PJ, Brasseur R, Culbertson MR, Humphries SE, Attie AD: Human apolipoprotein B
signal sequence variants confer a secretion-defective phenotype when expressed in yeast. J Biol Chem
1994;269:21670-21675.

Downloaded by:
University of Wollongong
130.130.37.85 - 12/10/2014 4:23:52 AM

Cellular Physiology
and Biochemistry

Cellular Physiology
and Biochemistry

63
64
65
66
67
68
69

DOI: 10.1159/000366345
Published online: October 02, 2014

© 2014 S. Karger AG, Basel
www.karger.com/cpb

1401

Rhein et al.: Function of the ASM Signal Peptide

Xu CF, Tikkanen MJ, Huttunen JK, Pietinen P, Butler R, Humphries S, Talmud P: Apolipoprotein B
signal peptide insertion/deletion polymorphism is associated with Ag epitopes and involved in the
determination of serum triglyceride levels. J Lipid Res 1990;31:1255-1261.
Saha N, Tay JS, Chew LS: Influence of apolipoprotein B signal peptide insertion/deletion polymorphism on
serum lipids and apolipoproteins in a chinese population. Clin Genet 1992;41:152-156.
Ng TW, Ooi EM, Watts GF, Chan DC, Barrett PH: Genetic determinants of apolipoprotein B-100 kinetics.
Curr Opin Lipidol 2010;21:141-147.
Halsall DJ, Martensz ND, Luan J, Maison P, Wareham NJ, Hales CN, Byrne CD: A common apolipoprotein
B signal peptide polymorphism modifies the relation between plasma non-esterified fatty acids and
triglyceride concentration in men. Atherosclerosis 2000;152:9-17.
Boekholdt SM, Peters RJ, Fountoulaki K, Kastelein JJ, Sijbrands EJ: Molecular variation at the apolipoprotein
B gene locus in relation to lipids and cardiovascular disease: A systematic meta-analysis. Hum Genet
2003;113:417-425.
Hegde RS: Targeting and beyond: New roles for old signal sequences. Mol Cell 2002;10:697-698.
Defour A, Van der Meulen JH, Bhat R, Bigot A, Bashir R, Nagaraju K, Jaiswal JK: Dysferlin regulates
cell membrane repair by facilitating injury-triggered acid sphingomyelinase secretion. Cell Death Dis
2014;5:e1306.
Perrotta C, Bizzozero L, Cazzato D, Morlacchi S, Assi E, Simbari F, Zhang Y, Gulbins E, Bassi MT, Rosa P,
Clementi E: Syntaxin 4 is required for acid sphingomyelinase activity and apoptotic function. J Biol Chem
2010;285:40240-40251.

Downloaded by:
University of Wollongong
130.130.37.85 - 12/10/2014 4:23:52 AM

62

Cell Physiol Biochem 2014;34:1385-1401

